SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

                                 AMENDMENT NO. 1

(Mark one)

|XX| Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934.

For the period ended June 30, 1999.

|___| Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934.

For the transition period from__ to__.

Commission File Number:                                                  0-16128

                              TUTOGEN MEDICAL, INC.
             (Exact name of registrant as specified in its charter)

Florida                                                               59-3100165
(State or other Jurisdiction of                                 (I.R.S. Employer
Incorporation or Organization)                               Identification No.)

1719 Route 10, Suite 314, Parsippany, New Jersey                           07054
(Address of Principal Executive Offices)                              (Zip Code)

Registrant's telephone number, including area code:               (973) 359-8444

Securities registered pursuant to Section 12(b) of the Act:                 None

Securities registered pursuant to Section 12(g) of the Act:

     Common Stock, par value $.01
           (Title of Class)          (Name of Each Exchange on Which Registered)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes |X| No|_|.

As of July 31, 1999 there were outstanding 10,853,188 shares of Tutogen Medical,
Inc. Common Stock, par value $0.01.
<PAGE>

                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES

                                      INDEX

                          Purpose of Amendment No. 1                     1

PART I.                   Financial Information.

              ITEM 1.     Financial Statements.

                          Consolidated Balance Sheets - June
                          30, 1999 and September 30, 1998.               2

                          Consolidated Statements of
                          Operations for the three and nine
                          months ended June 30, 1999 and 1998.           3

                          Consolidated Statements of Cash
                          Flows for the nine months ended
                          June 30, 1999 and 1998.                        4

                          Notes to Consolidated Financial
                          Statements.                                    5

              ITEM 2.      Management's Discussion and
                           Analysis of Financial Condition
                           and Results of Operations.                    7

PART II.                   Other Information.

              ITEM 6.      Exhibits and Reports on Form 8-K              10

SIGNATURES                                                               11
<PAGE>

                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES

                        PURPOSE OF AMENDED FORM 10-QSB/A

The Amended Form 10-QSB/A for the third quarter ended June 30, 1999 is being
filed to correct the accounting treatment of the conversion of the Company's
Convertible Debenture and accrued interest and expenses of approximately
$2,162,000 into 4,600,507 shares of common stock. In consideration of the
agreement to convert in advance of maturity, the Company issued to its
institutional investor 149,334 common shares as prepayment for one year's
interest on the Debenture.

The value of the additional shares was previously charged to additional paid-in
capital. The corrected accounting treatment reflects a loss on the conversion of
$187,000 and has been included as a charge against the profit and loss for the
second quarter ended March 31, 1999.

An Amended Form 10-QSB/A was filed for the second quarter ended March 31, 1999.
The purpose of this Amendment is to correct the cumulative nine months ended
June 30, 1999 results. The revised net loss for the first nine months ended June
30, 1999 is $614,000 versus the previously reported net loss of $427,000.


                                        1
<PAGE>

                          PART I. FINANCIAL INFORMATION

Item 1.  Financial Statements.

                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS
                                 (in thousands)

                                              (unaudited)    (audited)
                                                June 30,    September 30,
                                                  1999          1998
                                              ----------    -------------
ASSETS

Current Assets
    Cash and cash equivalents                   $   278       $   357
    Accounts receivable                           1,777         1,685
    Inventories                                   4,440         4,435
    Other current assets                            211           173
                                                -------       -------
                                                  6,706         6,650

Property, plant and equipment, net                2,547         2,995

Intangible and other assets, net                    279           596
                                                -------       -------
TOTAL ASSETS                                    $ 9,532       $10,241
                                                =======       =======

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities
    Accounts payable                              $ 652       $ 1,010
    Accrued interest                                136           189
    Other accrued expenses                          874           953
    Revolving credit arrangements                 1,018           895
    Current portion of long-term debt                70           162
                                                -------       -------
                                                  2,750         3,209

Other Liabilities
    Long-term debt                                1,406         3,644
    Other long-term obligations                      15            17

Shareholders' Equity                              5,361         3,371
                                                -------       -------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY      $ 9,532       $10,241
                                                =======       =======

See accompanying Notes to Consolidated Financial Statements.


                                        2
<PAGE>

                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                      (in thousands except per share data)

<TABLE>
<CAPTION>
                                           Three Months Ended June 30,    Nine Months Ended June 30,
                                           ---------------------------    --------------------------
                                                1999          1998          1999           1998
                                            -----------    ----------     ----------    ----------
<S>                                         <C>            <C>            <C>           <C>
OPERATING REVENUES
          Revenue                           $     2,549    $    2,348     $   7,822     $    6,261
          Cost of revenue                         1,416         1,124         4,506          3,386
                                            -----------    ----------     ---------     ----------
             Gross margin                         1,133         1,224         3,316          2,875

OPERATING EXPENSES
         General and administrative                 509           564         1,564          1,425
         Distribution and marketing                 483           404         1,489          1,071
         Research and development                    74            77           279            200
         Depreciation and amortization              114           167           361            523
                                            -----------    ----------     ---------     ----------
                                                  1,180         1,212         3,693          3,219

Operating (loss) profit                             (47)           12          (377)          (344)

License fee                                           -             -             -           (200)
Settlement of partnership interest                    -          (205)            -           (205)
Loss on conversion of debt                            -             -           187              -
Other (income) expenses                              13            (4)         (133)           (58)
Interest expense                                     45            98           183            278
                                            -----------    ----------     ---------     ----------
                                                     58          (111)          237           (185)
                                            -----------    ----------     ---------     ----------
Net (loss) profit before income taxes              (105)          123          (614)          (159)

Income taxes                                          -             -             -              -
                                            -----------    ----------     ---------     ----------
NET (LOSS) PROFIT                           $      (105)   $      123     $    (614)    $     (159)
                                            ===========    ==========     =========     ==========
Average common shares outstanding            10,851,707     5,316,570     8,925,453      5,017,178
                                            ===========    ==========     =========     ==========
Net (loss) profit per share                 $     (0.01)   $     0.02     $   (0.07)    $    (0.03)
                                            ===========    ==========     =========     ==========
</TABLE>

See accompanying Notes to Consolidated Financial Statements


                                        3
<PAGE>

                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENT OF CASH FLOWS
                                 (in thousands)

<TABLE>
<CAPTION>
                                                            Nine Months Ended June 30,
                                                            --------------------------
                                                                1999         1998
                                                               -------      -------
<S>                                                            <C>          <C>
Cash flows from operating activities
Net loss                                                       $  (614)     $  (159)
Adjustments to reconcile net loss to net cash
  used in operating activities:
  Depreciation and amortization                                    583          784
  Loss on conversion of debt                                       187            -
  Increase (decrease) in cash resulting from changes in:
     Accounts receivable                                           (92)        (168)
     Inventories                                                    (5)      (1,353)
     Prepaid expenses and other current assets                     (38)         (58)
     Accounts payable and accrued liabilities                     (169)        (109)
                                                               -------      -------
        Net cash used in operating activities                     (148)      (1,063)

Cash flows from investing activities
   Purchase of property, plant and equipment                      (176)        (128)
                                                               -------      -------
      Net cash provided by (used in) investing activities         (176)        (128)

Cash flows from financing activities
    Issuance of stock                                              458        4,295
    Proceeds from long-term borrowings                               -          500
    Proceeds (repayment) of short-term borrowings                  183       (3,946)
    Repayment of long-term debt                                    (48)        (129)
                                                               -------      -------
         Net cash provided by financing activities                 593          720

Effect of exchange rate changes on cash                           (348)         (56)

Net decrease in cash and cash equivalents                          (79)        (527)

Cash and cash equivalents at beginning of period                   357          777
                                                               -------      -------
Cash and cash equivalents at end of period                     $   278      $   250
                                                               =======      =======

-----------------------------------------------------------------------------------

Supplemental cash flow disclosures
      Interest paid                                            $   103      $   428
                                                               =======      =======
Schedule of noncash financing activities:
      Issuance of common stock in exchange for
          convertible long-term debt and accrued interest      $ 2,349      $     -
      Issuance of common stock for interest                        376            -
                                                               -------      -------
                                                               $ 2,725      $     -
                                                               =======      =======
</TABLE>

See accompanying Notes to Consolidated Financial Statements


                                        4
<PAGE>

                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
              NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
                                  June 30, 1999
                        (in thousands, except share data)

(1)   OPERATIONS AND ORGANIZATION

      Tutogen Medical, Inc. along with its consolidated subsidiaries ("the
      Company") processes, manufactures and distributes worldwide specialty
      surgical products and provides tissue processing services for neuro,
      orthopedic, cardiovascular, reconstructive and general surgical
      applications. The Company's core business is processing human donor tissue
      ("allografts") utilizing its patented Tutoplast(R) process for
      distribution to hospitals and surgeons.

(2)   SIGNIFICANT ACCOUNTING POLICIES

      The accompanying unaudited consolidated financial statements of the
      Company and the unaudited results of operations and cash flows for the
      three months ended June 30, 1999 and 1998 have been prepared in conformity
      with generally accepted accounting principles for interim financial
      reporting. Accordingly, they do not include all of the information and
      notes required by generally accepted accounting principles for complete
      financial statements. In the opinion of management, all adjustments
      necessary in order to make the financial statements not misleading have
      been made. Operating results for the three and nine months ended June 30,
      1999 are not necessarily indicative of the results which may be expected
      for the fiscal year ending September 30, 1999. The interim financial
      statements should be read in conjunction with the audited consolidated
      financial statements of the Company for the year ended September 30, 1998.

(3)   INVENTORIES

      Major classes of inventory at June 30, 1999 and September 30, 1998 were as
follows:

                                             June 30,    September 30,
                                               1999           1998

      Raw materials                           $1,362         $1,473
      Work in process                          2,787          2,729
      Finished goods                           1,142          1,249

      Less reserves for obsolescence            (851)        (1,016)
                                              ------         ------
                                              $4,440         $4,435
                                              ------         ------


                                        5
<PAGE>

(4)   SHAREHOLDERS' EQUITY

      On January 28, 1999, one of the Company's institutional investors
      converted its Convertible Debenture and accrued interest and expenses
      (approximately $2,162) into 4,600,507 shares of the Company's common
      stock. In consideration of the agreement to convert, the Company issued to
      the investor 149,334 common shares as prepayment for one year's interest
      on the Debenture and agreed to amend its outstanding Stock Purchase
      Warrants, totaling 1,353,957, by reducing the exercise price from $2.50
      per share to $1.25 per share if such warrants are exercised prior to June
      30, 2000, after which date such warrants shall revert to their initial
      terms.

      During the nine months ended June 30, 1999, this same institutional
      investor, a Director of the Company and private investors purchased
      300,000 Units, 100,000 Units and 57,500 Units, respectively, at $1.00 per
      Unit, each Unit consisting of one common share of the Company and one
      Common Stock Purchase Warrant, expiring March 31, 2000, at an exercise
      price of $1.50 per share.

(5)   DISTRIBUTION AGREEMENT

      On July 9, 1999, the Company entered into a Third Amendment to an
      Exclusive Distribution Agreement with Mentor Corporation "Mentor" for the
      purpose of granting a license to Mentor to exclusively distribute the
      Tutoplast(R) Processed Pericardium ("Pericardium") as an additional
      product in their field of use which is defined as all urological and
      gynecological applications and procedures in the United States and all
      foreign markets. In addition, processing fees were modified on selected
      other products under the Agreement. The initial term of the Pericardium
      license is ten years with an automatic renewal for successive terms of two
      full calendar years. The Company was paid a license fee of $300,000.


                                        6
<PAGE>

       ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
                            AND RESULTS OF OPERATIONS
                                 (in thousands)

Results of Operations

Net Loss

Net loss for the three months ended June 30, 1999 totaled $105 or $0.01 per
share as compared to a net income of $123 or $0.02 per share for the same period
a year ago. The net loss for the nine months ended June 30, 1998 was $614 or
$0.07 per share as compared to a net loss of $159 or $0.03 per share.

Revenue and Cost of Revenue

Revenue for the three months ended June 30, 1999 increased 9% to $2,549 from
$2,348 for the comparable period. The US operation revenues were $1,105 or 55%
higher than the same period last year. This is a direct result of its strategic
alliances with the Mentor Corporation and IOP, Inc. The International operation
had a decrease in revenues of 7% from the same period last year due primarily as
a result of the delay in adapting to revised standards for tissue processing
issued by the international regulatory body. The revenue for the nine months
ended June 30, 1999 increased 25% to $7,822 from $6,261 for the comparable
period. The revenues for the US operation were $3,123 or a 99% increase from
$1,573 for the same period last year. The revenues for the International
operation increased by 3% from the same period last year.

Gross margins for the three months ended June 30, 1999 were 44% and 52% for the
comparable period last year. The gross margins for the nine months ended June
30, 1999 decreased to 42% from 46% for the comparable period last year. The
decrease was primarily attributable to an unfavorable mix of products sold at
both the US and International operations.

General and Administrative

General and administrative expenses decreased 10% and increased 10% for the
three and nine months ending June 30, 1999, respectively, from the comparable
periods last year. The year-to-date increase was due primarily to an increase in
legal, consulting and travelling expenses.

Distribution and Marketing

Distribution and marketing expenses increased 20% and 39% for the three and nine
months ending June 30, 1999, respectively, from the comparable periods last
year. The increase was primarily associated with the building of a direct sales
force in Germany and the costs associated with the introduction of a new product
line, Tutoplast(R) bovine pericardium.

Research and Development

Research and development expenses decreased 4% and increased 40% for the three
and nine months ending June 30, 1999, respectively, from the comparable periods
last year. The year-to-date increase was due to the expansion of the R & D
effort in Germany and travelling and personnel costs to expand the tissue
recovery sites in Europe.


                                        7
<PAGE>

Depreciation and Amortization

Depreciation and amortization decreased 32% and 31% for the three and nine
months ending June 30, 1999, respectively, from the comparable periods last
year. The reduction in depreciation and amortization was attributed to an
increase in fully depreciated property, plant and equipment.

Interest Expense

Interest expense declined 54% and 34% for the three and nine months ending June
30, 1999, respectively, from the comparable periods last year. Lower interest
was the direct result of capital restructurings completed during the quarter
ending December 31, 1997 and the recent conversion of $2,074 of long-term debt
to common stock at the end of January of 1999.

Liquidity and Capital Resources

At June 30, 1999 and September 30, 1998 the Company had working capital of
$3,956 and $3,441, respectively. The Company maintains revolving credit
facilities totaling DM 2,360 (approximately $1,250) with three German banks. At
June 30, 1999 the Company had borrowed $961 against these lines.

In the past the Company has relied upon its available working capital lines and
institutional investors to fund operational cash flow, when needed. During this
year, one of the Company's institutional investors, a Director of the Company
and private investors purchased 300,000 Units, 100,000 Units and 57,500 Units,
respectively, at $1.00 per Unit, each Unit consisting of one common share of the
Company and one Common Stock Purchase Warrant, expiring March 31, 2000, at an
exercise price of $1.50 per share. In addition, the Company is continuing to
seek other investors to infuse additional capital into the Company. While
management believes that it will be successful in securing new funding, there
can be no assurances that it will be able to do so. Lack of new funding along
with the inability to increase processing revenues could result in a curtailment
of operations in the future.

The Company's ability to generate positive operational cash flow is dependent
upon increasing processing revenues through increased recoveries by tissue banks
in the U.S. and Europe, and the development of additional markets and surgical
applications worldwide. While the Company believes that it continues to make
progress in both these areas, there can be no assurances that changing
governmental regulations will not have a material adverse effect on results of
operations and cash flow.

Government Regulation

It has previously been reported in an SEC filing that the Food and Drug
Administration ("FDA") has raised a concern about the potential for transmission
of Creutzfeldt-Jacob Disease ("CJD") from one lot of Tutoplast(R) Dura Mater
processed by the Company in Germany before April 1994. The FDA and the Centers
for Disease Control and Prevention ("CDC") have investigated an incident in
which a patient who received a Tutoplast(R) Dura Mater transplant in 1992 was
diagnosed with CJD in 1998. Although there have been no other reports of disease
transmission associated with over 500,000 Tutoplast(R) Dura Mater transplants,
based on the investigation conducted by FDA and CDC, the Company cannot rule out
with absolute certainty at this time that Tutoplast(R) Dura Mater may have been
the possible cause of CJD in this incident.


                                        8
<PAGE>

Consequently, the Company has voluntarily recalled from the market all sizes and
lots of Tutoplast(R) Dura Mater processed in Germany before 1994 under the same
conditions as the lot that is the subject of FDA's concern. All sizes and lots
of Tutoplast(R) Dura Mater bearing an expiration date after April 1999 that were
processed by the Company's US operation at its facility in Alachua, Florida
since April 1994, under conditions that meet current United States and
International standards and regulatory requirements, are not involved. There has
been no recall requested by the German health authorities. However, they have
raised the regulatory requirements on dura mater. The Company will comply with
these new requirements.

There have been minimal returns of product in the U.S., it will take several
weeks to comply with the new requirements in Germany. Meanwhile, the Company is
offering alternative tissues such as fascia lata and bovine pericardium to the
market. Nevertheless, the impact of the delay in supplies caused by the new
requirements on dura mater is estimated to be a loss of $350,000 in revenues and
reduced profits of $210,000 for the fiscal year.

Year 2000 Compliance

Management has recently become aware that one of the operating systems in the
International operations is not currently Year 2000 compliant. The International
operation is currently implementing a new operating system, which will encompass
the necessary amendments for the system to become Year 2000 compliant. The
implementation is expected to be completed by September 1999. The costs of the
Year 2000 upgrade are included in the overall implementation cost, and
therefore, are not separately identifiable.


                                        9
<PAGE>

PART II. OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K.

        Exhibits

        No. 27            Financial Data Schedule

        No reports on Form 8-K were filed by the Company during the quarter
        ended June 30, 1999.


                                       10
<PAGE>

SIGNATURES

Registrant has duly caused this report to be signed on its behalf by the
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
undersigned, thereunto duly authorized.

                                    Tutogen Medical, Inc.


Date: August 9, 1999                /s/ Charles C. Dragone
                                    -----------------------
                                    Interim Chief Executive Officer


Date:  August 9, 1999               /s/ George Lombardi
                                    -----------------------
                                    Chief Financial Officer
                                    (Principal Financial and Accounting Officer)


                                       11